<DOC>
	<DOC>NCT00266669</DOC>
	<brief_summary>The purpose of this study is to investigate the efficacy and safety of a topical gel formulation of nitroglycerin, in comparison to a matching placebo, for patients with moderate to severe primary Raynaud's phenomenon or patients with Raynaud's phenomenon secondary to autoimmune diseases, such as scleroderma.</brief_summary>
	<brief_title>Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon</brief_title>
	<detailed_description />
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Nitroglycerin</mesh_term>
	<criteria>Clinical diagnosis of Raynaud's phenomenon 2 or more Raynaud's events on a typical winter day Agree to discontinue current treatments for Raynaud's Negative pregnancy test and agree to use effective contraception during study Current use of nitrate medications or medications known to interact with nitroglycerin Patients who currently use medications, like calcium channel blockers, that might interfere with study medication Patients with a known allergy to nitroglycerin or common topical ingredients Patients with a history of migraine headaches Patients with a history of unstable medical problems Patients with cognitive or language difficulties that would impair completion of assessment instruments Patients with lab screening values more than 20% outside normal range Patients with nonepithelialized skin lesions, in the area where the gel is to be applied, at the time of screening Pregnant or nursing women Women of childbearing potential who are unwilling to comply with the contraceptive requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Raynaud's Phenomenon</keyword>
	<keyword>Raynaud's Disease</keyword>
	<keyword>Scleroderma</keyword>
	<keyword>Raynaud's Disease Secondary to Scleroderma</keyword>
	<keyword>Raynaud's Disease Secondary to Other Autoimmune Disease</keyword>
</DOC>